September 15, 2010,
11:30-1:00 pm EDT
Instructor: Mark Bamberger, Ph.D., Independent Pharmaceutical Research Consultant, Former Research Fellow and Director of Cardiovascular Research. Pfizer Inc.
Learning Objectives:
Genetic variation in humans
Animal models including genetic variants (knock-outs, transgenic, naturally occurring, etc.)
Gene expression, proteomics and pathway analysis in humans with disease phenotype
Drug prototypes
Real examples
Who Should Attend:
Bench level scientists interested in the bigger picture in drug discovery
Drug discovery project leaders, especially first-timers
Academic researchers interested in turning basic science discoveries into therapies
Individuals involved in funding drug discovery start-ups
Non-scientists managing drug discovery efforts
Instructor Bio:
Mark is a pharmaceutical professional with 20 years of diverse scientific and executive experience encompassing drug discovery and early clinical development, primarily in the cardiovascular area. As former Director of Atherosclerosis Research at Pfizer, he provided the strategy resulting in the initiation of multiple new target programs and the nomination of over a dozen compounds for advancement to clinical development. He has extensive experience leading cross-disciplinary teams for the progression of candidate compounds through pre-clinical studies and Phase 1 human trials, along with setting strategy for Atherosclerosis, including potential mechanisms and clinical endpoints for in-house and licensing efforts.
Mark received his Ph.D. in Biochemistry from the Medical College of Pennsylvania, and completed a postdoctoral fellowship in the Dept. of Biological Chemistry at the Johns Hopkins University School of Medicine. He is the author of numerous publications and is currently of Fellow of the American Heart Association.